PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Molecular imaging finds hurdle for smokers' vaccine

Anti-nicotine vaccination as seen by PET imaging leads to disparity in natural immune response and in some cases can actually increase accumulation of nicotine in the brain

2013-06-11
(Press-News.org) Vancouver, British Columbia – Researchers have yet again been sent back to the drawing board in the development of the much-sought-after vaccination for smokers, which would hypothetically inhibit the action of nicotine and its pleasure-producing chemical response in the brain. One of the newest studies of a proposed vaccine shows mixed results for patients after molecular imaging revealed no desirable effect and potentially allowed even more nicotine accumulation in the brain in some cases due to variations in immune response, say neuroscientists at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

The objective of such a vaccine, when developers reach their goal, would be to kill the high that perpetuates people's addiction, thereby improving the odds that they can quit smoking. "Everyone knows that smoking is bad—it causes diseases that can be fatal and it is an expensive habit—but there are currently no drug treatments available that can help a majority of smokers achieve long-term abstinence," said Alexey G. Mukhin, MD, PhD, professor of psychiatry and behavioral science at Duke University Medical Center in Durham, NC. "This research represents one of the first human studies of its kind using molecular imaging to test an investigational anti-nicotine immunization and how it affects the accumulation of nicotine in the brain during smoking."

Antibodies, also called immunoglobulin, are the ground patrol of the immune system. These proteins scavenge for viruses, bacteria and foreign material. The anti-nicotine immunization introduces an antigen that induces production of antibodies that bind circulating nicotine and prevent it from crossing the blood-brain barrier to produce rewarding effects in smokers.

"In order to work, one milligram of the nicotine from smoking one cigarette needs about a half a gram of antibody for proper attachment and prevention of interaction with brain nicotinic receptors," said Yantao Zuo, PhD, assistant professor also in the department of psychiatry and behavioral sciences at Duke University Medical Center. "A very high number of antibodies is needed to negate the effects of nicotine from one pack of cigarettes—up to 10 percent of the 100 grams of antibodies we have available in the body. To complicate matters, not all vaccination-induced antibodies are the same. Some have high affinity to nicotine and bind strongly, while others bind with lower affinity."

The practical result of this is that if the binding of nicotine with antibodies is weak and the nicotine-antibody bond breaks during passage of the blood through the brain, potentially more nicotine could flood brain nicotinic receptors.

"Investigational anti-nicotine vaccines like this one produce non-uniform effects," said Mukhin. "Ideally we want it to decrease amount of nicotine that reaches the brain, but when we compared the immune response across subjects, their antibodies appeared to vary in nicotine-binding properties. Findings from positron emission tomography, otherwise known as PET, showed that strong nicotine-antibody binding, which means high affinity, was associated with a decrease in brain nicotine accumulation. When binding was not strong, an increase in brain accumulation was observed. These results are important because they tell us that we should care about not only the amount of antibody but the quality of the antibody. We don't want to have low-affinity antibodies, because that can negate anti-nicotine effects of the vaccination."

For this study, people who smoke more than 10 cigarettes a day were enrolled and asked to smoke during two scheduled PET brain scans. The first procedure occurred before patients were given an injection of NIC002, a novel anti-nicotine vaccine provided by Novartis and in-licensed from Cytos. Three more injections were given, and two weeks after the last dose, PET imaging was repeated. Each brain scan involved patients taking a single puff of a cigarette containing S-nicotine labeled with radioactive C-11, which can be detected by a PET scanner.

Results showed that the 10 subjects with highest vaccination-induced serum capacity to bind nicotine had high-affinity antibodies and experienced a slight but statistically significant decrease in nicotine brainaccumulation. Another 10,who had intermediate serum nicotine binding capacity and low affinity of antibodies, showed the opposite—an increase in brain accumulationof nicotine. The remaining nine, with the lowest serum nicotine binding capacity, showed little change. While this was not the result researchers hoped for, it adds to a body of research that could lead one day to an effective vaccine. Most likely, such a vaccine would be developed at least 5-10 years down the road, estimated Mukhin.

"This will lead to further studies, as a variety of concepts for anti-nicotine vaccinationare being developed to treat this addiction," said Zuo. "The development of a safe and effective vaccine treatment for nicotine addiction could have a profound effect on many people's lives in terms of overall health and disease prevention. With reports of new generations of the vaccines showing potentially much higher potencies in animal studies, we are hopeful that our current findings and methodology in human research will facilitate understanding of how these work in smokers."

Approximately 45.3 million American adults, or just over 19 percent, are estimated to smoke. Cigarette smoking is the number one cause of preventable death in the country and is directly implicated in coronary heart disease—the leading cause of death—as well as lung cancer and other deadly lung diseases. The habit results in about 443,000 deaths, or one in five, across the United States annually. Smoking can lead to 23 times the risk of cancer for men, and 13 times the risk in women, according to the U.S. Centers for Disease Control and Prevention.

### Scientific Paper 30: Alexey Mukhin, Yantao Zuo, Frederique Behm, Jed Rose, Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC; Sudha Garg, Rachid Nazih, Pradeep Garg, Radiologic Sciences, Wake Forest University Baptist Medical Center, Winston-Salem, NC; Ivan Bottoli, Novartis Pharma AG, Basel, Switzerland, "Effect of anti-nicotine immunization with NIC-002 vaccine on brain nicotine accumulation during cigarette smoking," SNMMI's 60th Annual Meeting, June 8, 2013, Vancouver, British Columbia.


ELSE PRESS RELEASES FROM THIS DATE:

High sugar intake linked to low dopamine release in insulin resistant patients

2013-06-11
Vancouver, British Columbia – Using positron emission tomography (PET) imaging of the brain, researchers have identified a sweet spot that operates in a disorderly way when simple sugars are introduced to people with insulin resistance, a precursor to type 2 diabetes. For those who have the metabolic syndrome, a sugar drink resulted in a lower-than-normal release of the chemical dopamine in a major pleasure center of the brain. This chemical response may be indicative of a deficient reward system, which could potentially be setting the stage for insulin resistance. This ...

Radiopeptide therapy improves survival outcomes for neuroendocrine cancer patients

2013-06-11
Vancouver, British Columbia – Peptide-receptor radionuclide therapy (PRRT) has been a subject of growing research on neuroendocrine tumors, which take up residence in a variety of organs replete with nerve cells that respond to hormone signaling. A countrywide study in Germany deemed PRRT treatment not only safe and effective but life-prolonging, according to a study unveiled during the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting. PRRT is a new and yet-to-be-approved treatment for patients with neuroendocrine tumors (NETs). These develop when ...

Molecular imaging enlists prostate enzyme to detect metastases

2013-06-11
Vancouver, British Columbia – No matter where they have hidden, metastatic prostate cancer cells still express some of the same signaling as normal prostate cells; in some cases even more so, as with the PSMA enzyme. Harnessing this enzyme could mean the beginning of a new platform for prostate cancer detection, staging, treatment and post-treatment monitoring, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting. "There are currently no ideal imaging techniques in clinical practice that are specific to prostate cancer," said ...

Radioimmunotherapy could extend lives of advanced lymphoma patients

2013-06-11
Vancouver, British Columbia – A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients' lymphoma can be eradicated as they prepare for bone marrow transplant, say researchers at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging. In a study presented at the meeting, survival rates without recurrence improved with the addition of RIT, with some having a 100 percent chance of survival ...

Breast cancer: PET and MR predict chemotherapy's ability to prolong life

2013-06-11
Vancouver, British Columbia – For patients with advanced breast cancer, positron emission tomography (PET) and magnetic resonance (MR) imaging can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, say researchers presenting at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging. Researchers combined separate imaging systems—PET, MR and CT—to map the course of chemotherapy before surgery, otherwise known as neoadjuvant chemotherapy. These different imaging systems ...

PET/MR effective for imaging recurrent prostate cancer

2013-06-11
Vancouver, British Columbia – When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to plan the best possible treatment. A relatively new imaging system that simultaneously combines positron emission tomography and magnetic resonance (PET/MR) demonstrates a higher capacity for mapping recurrent prostate cancer than the already high standard of integrated PET and computed tomography (PET/CT), say researchers presenting ...

Hormonal treatment for endometrial cancer does not directly target the malignant cells

2013-06-11
Progesterone, a female hormone that can be used as a therapy for endometrial cancer, eliminates tumor cells indirectly by binding to its receptor in stromal or connective tissue cells residing in the tumor microenvironment, according to a study from the G.O. Discovery Lab team and collaborators at UCLA. Like tumors of the breast and prostate, endometrial cancer is regulated by hormones. Unlike therapies for breast and prostate cancer, where drugs are given to block hormone signaling, in therapy for endometrial cancer progesterone is given to stimulate its hormone receptor. ...

Plunging fish numbers linked to dam releases

2013-06-11
A significant decline in the numbers of native fish in Australia's Murray-Darling Basin may be linked to released dam water being too cold for breeding. This is just one of the findings from a Griffith University led study which found current water releases back into the Murray-Darling system limit fish reproduction and therefore impact freshwater biodiversity. Griffith University Research Fellow Dr Rob Rolls said the results, published in Freshwater Biology, throw cold water on the notion that large dam releases compensate for the effects of interrupting natural water ...

Screening fails to affect breast cancer mortality statistics

2013-06-11
New research analysing breast cancer mortality data spanning almost 40 years concludes that breast cancer screening does not yet show an effect on mortality statistics. The research, published in the Journal of the Royal Society of Medicine, analysed mortality trends before and after the introduction of the National Health Service Breast Screening Programme in 1988. The research was based on an analysis of mortality statistics in the Oxford region because, unlike the rest of England, all causes of death on the death certificate, not just the underlying cause, are available ...

'Popcorn' particle pathways promise better lithium-ion batteries

2013-06-11
LIVERMORE, Calif.— Researchers at Sandia National Laboratories have confirmed the particle-by-particle mechanism by which lithium ions move in and out of electrodes made of lithium iron phosphate (LiFePO4, or LFP), findings that could lead to better performance in lithium-ion batteries in electric vehicles, medical equipment and aircraft. The research is reported in an article entitled, "Intercalation Pathway in Many-Particle LiFePO4 Electrode Revealed by Nanoscale State-of-Charge Mapping" in the journal Nano Letters, 2013, 13 (3), pp 866-872. Authors include Sandia physicist ...

LAST 30 PRESS RELEASES:

Columbia University Fertility Center named #1 by Newsweek

Two prominent Boston Children's Hospital scientists elected to National Academy of Sciences

Vegetation changes accelerated climate shifts during the late Miocene, study finds

Scientists discover key to taming unrest at Italy’s Campi Flegrei

Study reveals details of process driving evolution and major diseases

NCSA director Bill Gropp honored with prestigious ACM award

The future of brain activity monitoring may look like a strand of hair

New gene-editing therapy shows early success in fighting advanced GI cancers

nTIDE May 2025 Jobs Report: Employment of People with Disabilities Remains in a Holding Pattern

SCAI honors members for outstanding service and dedication

NRG Oncology adds new committee leaders in lung cancer and imaging

Sun safety declining in Canada amid rise in skin cancer cases

Pennington Biomedical highlights how cellular quality control contribute to insulin resistance related to type 2 diabetes

ACM honors those who shape technology's future

ESE and ESPE joint event to call for stronger national and EU action on endocrine disruptors

Call for papers: Commemorative collection honoring Dr. Judith Campisi

New studies highlight potential of artificial intelligence to improve outcomes for patients with heart failure and cardiac arrest

Space junk falling to Earth needs to be tracked. Meteoroid sounds can help

Dust in the system — How Saharan storms threaten Europe’s solar power future

“It’s like they have a superpower”: Genetic analysis of all-women extreme divers finds changes linked to blood pressure, cold tolerance

The all-female Korean Haenyeo divers show genetic adaptions to cold water diving

Antivenom neutralizes the neurotoxins of 19 of the world’s deadliest snakes

Postpartum care differences in LGBTQ+ and non-LGBTQ+ individuals

Medicaid unwinding linked to disruptions in opioid addiction treatment

State-level tax policy, cancer screening, and mortality rates in the US

Lactate mediates training of our innate defenses

Sutter Health study highlights the power and potential of ambient AI to improve clinician well-being

How mid-Cretaceous events affected marine top predators

How will 13 million farmers fight back against sea level rise? New global model simulates adaptation, migration, and survival in the face of climate crises

PSU study gauges public's willingness on microplastic interventions

[Press-News.org] Molecular imaging finds hurdle for smokers' vaccine
Anti-nicotine vaccination as seen by PET imaging leads to disparity in natural immune response and in some cases can actually increase accumulation of nicotine in the brain